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Abstract 
Background: Late stage Alzheimer’s disease and other dementias are associated with 
neurofibrillary tangles and neurodegeneration. Here we describe a mouse (TauD35) 
carrying human Tau with the P301L mutation that results in Tau hyperphosphorylation 
and tangles.  Previously we have compared gene expression in TauD35 mice to mice 
which develop plaques but no tangles. A similar comparison of other pathological 
features throughout disease progression is made here between amyloidβ and Tau mice 
described in Parts I and II of this study. 
 
Methods: In vitro CA1 patch clamp and field recordings were used to investigate 
synaptic transmission and plasticity. Plaque load and microglia were investigated with 
immunohistochemistry. Cognition, locomotor activity and anxiety-related behaviours 
were assessed with a forced-alternation T-maze, open field and light/dark box. 
 
Results: Transgene copy number in TauD35 mice fell into two groups (HighTAU and 
LowTAU), allowing assessment of dose-dependent effects of overexpression and 
resulting in tangle load increasing 100-fold for a 2-fold change in protein levels. Tangles 
were first detected at 8 (HighTAU) or 13 months (LowTAU) but the effects on synaptic 
transmission and plasticity and behaviour were subtle.  However, severe 
neurodegeneration occurred in HighTAU mice at around 17 months, preceded by 
considerable proliferation and activation of microglia at 13 months of age; both 
increasing further at 17 months. LowTAU mice at 24 months of age showed a 
comparable tangle load and microglial proliferation to that occurring at 13 months in 
HighTAU mice. However, LowTAU mice showed no neurodegeneration at this stage and 
considerable microglial activation, stressing the dependence of these effects on 
overexpression and/or age. 
 
Conclusions: Comparison of the effects of amyloidβ and plaques without tangles in a 
model of preclinical Alzheimer’s disease to the effects of tangles without amyloidβ 
plaques in the late stage model described here may clarify the progressive stages of 
Alzheimer’s disease.  While Tau hyperphosphorylation and neurofibrillary tangles are 
eventually sufficient to cause severe neurodegeneration, initial effects on synaptic 
transmission and the immune response are subtle. In contrast while even with a heavy 
plaque load little if any neurodegeneration occurs, considerable effects on synaptic 
transmission and the immune system result, even before plaques are detectable.  
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Background 
The prevalence of dementia in the ageing population is becoming a major problem for 
the health care system. Understanding the progression of the disease and the links 
between pathology and cognitive outcomes is essential if we are to find ways of slowing 
or preventing the onset of dementia. Alzheimer’s disease is the most common form of 
dementia and, in its later stages, shares common pathologies with frontotemporal 
dementia and other tauopathies. In all these dementias, the development of 
neurodegeneration is closely correlated with the hyperphosphorylation of the 
microtubule associated protein Tau and development of neurofibrillary tangles. In the 
case of Alzheimer’s disease this development is subsequent to a rise in amyloidβ (Aβ) 
and deposition of plaques, whereas some of the other tauopathies occur as a direct 
result of mutations in the Tau gene. 
To study the relative time course of synaptic and microglial changes and 
neurodegeneration in relation to phosphorylation of Tau and neurofibrillary tangles, we 
have characterised a novel strain of mice (TauD35), transgenic for MAPT, which encodes 
human Tau protein with a mutation that, in man, results in frontotemporal dementia 
with parkinsonism linked to chromosome 17 [1]. The pathology in this mouse progresses 
much more slowly than previously described models of Tauopathy [2, 3]. Previously we 
have correlated gene expression and development of neurofibrillary tangles in this 
mouse and undertaken gene expression network analysis  finding that most gene 
expression changes, including upregulation of microglial genes and decrease in 
expression of synaptic genes, occur only very late in disease progression, months after 
neurofibrillary tangles become evident [1]. This is in contrast to more aggressive 
overexpression models in which neurodegeneration occurs at a young age and synaptic 
changes are seen even before neurofibrillary tangles are evident [4]. A very interesting 
study in another Tau model showed synaptic and behavioural changes in middle age 
(approximately 10 months) which were reversible on turning off the transgene [5, 6]. 
However, further work is required to elucidate the mechanisms of this progression [7]. It 
is thought that neurofibrillary tangles may underlie neuronal death by interfering with 
axonal transport but mitochondrial dysfunction, leading to calcium homeostasis 
breakdown and apoptosis, likely also contributes [7]. Evidence suggests that caspases are 
involved, especially at earlier stages [8-10] in these aggressive models but in the slower 
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progressing model TauD35 mice, while some caspases show increased expression, this 
again occurs only late in disease progression [1; www.mouseac.org].  
The more aggressive models, such as rTg4510, are useful in that they start to 
develop neurofibrillary tangles very early and show rapid neurodegeneration, which is 
convenient in terms of cost and various practical considerations and interesting data 
have emerged [2, 3]. However, it makes the separation of stages of disease progression 
difficult and means that it occurs in mice at ages equivalent to adolescence through to 
early middle age rather than old age, as is most common in Alzheimer’s disease. In the 
present study we characterised mice developed at GlaxoSmithKline (TauD35) with the 
MAPTP301L mutation also on the CamKIIα promoter (the same mutation and promoter as 
for the rTg4510 mice but with much slower progression of pathology). During this study 
we established that the TauD35 line in fact consisted of two lines of these mice with 
different copy numbers (referred to here as LowTAU and HighTAU) enabling us to 
assess the dependency of changes seen on the gene dosage, albeit post hoc.  
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Methods  
Methods are the same as for [11] except adapted for neurofibrillary tangles. 
Animals 
All experiments were performed in agreement with the Animals (Scientific Procedures) 
Act 1986, with local ethical approval and in agreement with the GlaxoSmithKline 
statement on use of animals. 
Transgenic TauD35 male mice were generated by GlaxoSmithKline (Harlow, UK) 
on the background mouse line C57Bl/6J (Charles River, UK) via pronuclear injection and 
bred and maintained at Charles River Laboratories. The mice harbour human cDNA for 
the 0N4R isoform of MAPT carrying the P301L mutation under the alpha isoform of the 
Ca2+/calmodulin dependent protein kinase II (CaMKII) promoter. Age-matched wild 
type littermates were used as controls. 
 Mice from Charles River were shipped to UCL at 3-months-old. Mice were kept in 
large cages (20 x 35 x 45 cm) with an enriched environment. Thus, cages containing 2-8 
male mice (TauD35 and littermate wild type controls) were maintained in a 12-hour 
light/12-hour dark cycle with food and water ad libitum. Environmental enrichment 
consisted of changes of food location, bedding type (e.g. tissue, shredded paper, paper 
roll, paper bags) and inanimate objects (e.g. running wheels, rodent balls, tubing, houses 
(mostly purchased from Eli Lilly Holdings Limited, Basingstoke, UK)) within the cage at 
least once per week.  Mice were used for experimentation at the ages stated (± 0.5 
months) and, where unavoidable, were single-housed for no longer than 24 hours. Tails 
or ear punches were genotyped using standard PCR protocols. 
 
Genotyping 
Genotype confirmation using conventional PCR methods 
Briefly, genomic DNA was extracted using the ‘HotSHOT’ lysis method. Alkaline lysis 
reagent (25 mM NaOH, 0.2 mM EDTA, pH12) was added to tissue samples prior to 
heating to 95°C for 30 minutes. The sample was then cooled to 4°C before the addition of 
neutralisation buffer (40 mM Tris-HCl, pH 5). The PCR reaction was performed through 
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using the cycling parameters: 94°C (2 minutes), 58°C (30 s), 72°C (30 s), for 30 cycles 
and a final extension at 72°C for 4 minutes. PCR product size 130 bp. 
 
Transgene copy number confirmation 
Genomic DNA was extracted using the ‘HotSHOT’ lysis method described above. Unique 
TaqMan primer and probe sequences were generated using Applied Biosystems custom 
design sequence using the published sequence for the CaMKIIα promoter sequence 
(Accession# AJ222796). The qPCR assay was run with 4 μl of genomic DNA per well 
using the CaMKIIP_CCVI3TR primer and probe set (catalogue number 4400294, Applied 
Biosystems), using the Taqman genotyping master mix with each sample run in 
triplicate in parallel with the Taqman copy number reference assay for mouse 




Brain tissue extraction 
Brains were removed from the skull on ice and hippocampus extracted within 5 minutes 




Mouse hippocampal samples were sonicated (Branson Sonifier, 450) for 30 s at 9-12 W 
in RIPA buffer (1% [v/v] Triton X-100, 1% [w/v] sodium deoxycholate, 0.1% [w/v] SDS, 
0.15 M NaCl, 20 mM Tris-HCl (pH 7.4), 2 mM EDTA (pH 8.0), 50 mM NaF, 40 mM β-
glycerophosphate, 1 mM EGTA (pH8.0), 2 mM sodium orthovanadate, protease inhibitor 
tablet (cat no 11 836 153 001; Roche), aprotinin and phosphatase inhibitor cocktail 1 
and 2 (1:100; Sigma), 1 mM PMSF: approximately 1 ml for 100 mg tissue).  
For total protein extracts, homogenates were spun at 18,000 g for 10 minutes at 
4°C and the supernatant collected. Sample buffer (312.5 mM Tris (pH 6.8), 10% [w/v] 
SDS, 250 mM DTT, 50% [v/v] glycerol, 0.025% [w/v] bromophenol blue) was added 
prior to boiling the samples at 95°C for 10 minutes and storing at -20°C. 
 Sarkosyl-insoluble tau extracts were obtained as described previously [3] 90µl of 
homogenate was ultracentrifuged at 150,000g for 15 minutes at 4°C. The supernatant 
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(S1) was removed for storage and the pellet re-homogenised in 4 volumes of 10mM Tris 
(pH 7.4), 0.8M NaCl, 1mM EGTA, 10% sucrose, 1mM PMSF and ultracentrifuged as 
above. The resulting pellet was discarded and the supernatant incubated with 1% 
sarkosyl (30% sarkosyl NL30, BDH) for 1hr at 37°C, prior to ultracentrifugation at 
150,000g for 30 minutes at 4°C. The supernatant was again collected for storage (S2) 
and the pellet re-suspended in 20µl 10mM Tris (pH 8) and 1mM EDTA and labelled P3: 
sarkosyl insoluble tau. Sample buffer (312.5mM Tris (pH 6.8), 10% [w/v] SDS, 250mM 
DTT, 50% [v/v] glycerol, 0.025% [w/v] bromophenol blue) was added to all fractions 
prior to boiling the samples at 95°C for 10 minutes and storing at -20°C. 
 
Western blot analysis 
Protein corrected (Bradford assay) samples were resolved by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) using 8-10% polyacrylamide gels. 
Molecular weights were verified using a molecular weight standard (BioRad, #161- 
0374). Proteins were transferred to a nitrocellulose membrane (0.45 μm, BioRad) using 
electroblotting (30 V, overnight). Following transfer, membranes were washed in Tris-
buffered saline (Tris), prior to blocking against non-specific antibody binding in 5% 
milk/Tris for 1 hour at room temperature. Membranes were incubated in primary 
antibody in 5% milk/Tris overnight at 4°C. Following overnight incubation, membranes 
were washed in 0.05% Tween-20/Tris for five changes of 7 minutes each at room 
temperature and then for 10 minutes in 5% milk/Tris. Horseradish peroxidase-
conjugated goat anti-mouse (1:10,000; Jackson ImmunoResearch, #115-035-146) 
incubation was performed in 5% milk/Tris for 1 hour at room temperature. Membranes 
were washed again for five changes of 7 minutes in 0.05% Tween-20/Tris at room 
temperature, before a final wash of 5 minutes in Tris. Peroxidase activity was revealed 
using an enhanced chemiluminescence detection kit (ECL, Amersham). Image 
acquisition and densitometric analysis was performed using ImageLab (v4.1, BioRad) as 
described [12]. Density values for bands of interest were normalized against heat shock 
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Antibodies used for western blots and immunohistochemistry: (for review see [13]) 















N/A 1:300 Pierce Antibodies 
(MN1020B) 
DA9 Tau  
102-140  
 
Pan Tau 1:5000 N/A Gift from Peter 
Davies, Albert 
Einstein College of 
Medicine 
CP13 pS202 Early p-Tau 
[15] 








1:1000 1:200 Gift from Peter 
Davies 
MC1 Tau 7-9 and 
326-330,  
Conformation 
change [16, 17] 
N/A 1:200 Gift from Peter 
Davies 
IBA1 IBA1 Microglia [18] N/A 1:500 Wako (019-
19741) 
CD68 CD68 Activated/ 
phagocytic 
microglia 




Animals were deeply anaesthetised (1:10 Euthatal:Intra-Epicaine, National Veterinary 
Supplies) and transcardially perfused with 0.1 M phosphate buffer saline (PBS) followed 
by 10% buffered formal saline (Pioneer Research Chemicals Ltd). Alternatively, single 
hemispheres were drop-fixed immediately following brain extraction for 
electrophysiology. The brains were post-fixed in 10% buffered formal saline for 24hrs 
and cryoprotected in 30% sucrose/0.03% sodium azide/PBS at 4 C for at least 24hrs 
before sectioning or storage. Transverse sections were cut at 30 μm through the full left 
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hippocampus using a frozen sledge microtome (SM 2000 R, Leica) and collected into a 
24-well plate containing PBS/sodium azide (0.03%) for storage at 4°C. Serial sections 
were placed in separate wells until all wells contained a section and collection then 
continued serially from Well 1 so that within each well the transverse sections were 
from the length of the hippocampus at least 720µm apart. 
Standard immunohistochemistry techniques were employed.  Sections for all 
immunohistochemistry were washed in PBS, followed by 0.3% Triton X-100 in PBS 
(PBST) and subsequent blocking in 8% horse serum/PBST for 1 hour. Incubation with 
primary antibody in blocking solution was performed overnight at 4°C. Sections were 
again washed with PBST. The appropriate Alexa-conjugated secondary antibody (1:500; 
Invitrogen) was added to blocking solution for a 2-hour incubation at room temperature 
in the dark. Following PBS wash, DAPI was applied to all sections for 5 minutes. Sections 
were washed for a final time in PBS before mounting. Sections from age-matched wild 
type control mice were stained in parallel for all ages. Sections were mounted in 
anatomical order onto SuperFrost Plus glass slides by floating on PBS and then cover-
slipped using Fluoromount G mounting medium. 
 
Nissl Stain 
Sections were mounted and left to dry overnight prior to staining. Sections were dipped 
in H20 and then submerged in 1% w/v cresyl violet (Alfa Aesar, Massachusetts) for 2 
minutes and blotted to remove excess solution. Sections were de-stained in 70% ethanol 
containing 1% glacial acetic acid for <1 minute and then dried by submersion in 100% 
ethanol for 2 minutes followed by submersion in xylene (3 minutes) to completely 
remove water. Sections were then cover-slipped using DPX mounting medium. 
  
Imaging and data analysis 
Sections were imaged for quantification using an EVOS FL Auto Cell Imaging System 
(Life technologies). For immunohistochemistry and Nissl staining, tiled images were 
taken of the whole (transverse) hippocampus using a 20X objective. For 
immunohistochemistry and cell counts an area of 400 μm x 240 μm was defined in the 
CA1 and CA3. Cell counts were performed using Adobe Photoshop CS6. Iba1-positive 
microglia were only counted if a DAPI-positive nucleus was also present. Neurofibrillary 
tangle counts for double labelled sections (AT8/HT7) included only cells positive for 
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both antibodies. Cell counts using Nissl staining included all principle cells within the 
defined area, with cells identified by their morphology. Due to high density Nissl staining 
in the dentate gyrus, cell counts could not be reliably obtained for this area. Where 
neurofibrillary tangles/cells could not be individually distinguished, but stain was 
present, a count of 1 was awarded. Neurofibrillary tangle and cell counts are therefore 
an underestimate of true number. Sample sizes reported for immunohistochemistry and 
cell counts indicate the number of animals used to calculate means. A minimum of 3 
sections were used to create a mean for each animal. Sections for any given condition 
were obtained from the same collection well within the 24-well plate and were therefore 
a minimum of 720 μm apart, thus avoiding multiple counts of the same cells. Confocal 
images were taken using a laser scanning confocal microscope (Zeiss LSM 510) with a 
60X Plan-Apochromat oil immersion objective (1.4 numerical aperture). 
 
Electrophysiological recordings 
Acute hippocampal brain slice preparation 
Mice were decapitated and the brain rapidly removed and placed in ice-cold dissection 
artificial cerebrospinal fluid (ACSF, containing (in mM): 125 NaCl, 2.4 KCl, 26 NaHCO3, 
1.4 NaH2PO4, 20 D-glucose, 3 MgCl2, 0.5 CaCl2, pH 7.4, ~315 mOsm/l).  After 
approximately two minutes in ice-cold dissection ACSF, the brain was prepared for 
slicing by removing the cerebellum, hemisection of the forebrain and a segment cut 
away from the dorsal aspect of each hemisphere at an angle of approximately 110° from 
the midline surface to optimise slicing transverse to the hippocampus.  Each hemisphere 
was then glued with cyanoacrylate (Loctite 406, Henkel Loctite Limited, UK) on this 
surface onto the stage of a vibrating microtome (Integraslice model 7550 MM, Campden 
Instruments, Loughborough, UK) containing frozen dissection ACSF and 400 μm 
transverse slices of hippocampus cut.  As each slice of a hemisphere was cut, the 
hippocampus was dissected out, retaining a portion of entorhinal cortex and the 
resulting smaller slice was placed into a chamber containing ‘Carbogenated’ (95% 
O2/5% CO2; BOC Limited) dissection ACSF at room temperature (approximately 21°C).  
After 5 minutes, slices were then transferred into a fresh chamber held at 36°C with the 
same dissection ACSF.  At 5-minute intervals, they were then consecutively transferred 
to physiological Ca2+ and Mg2+ ion concentrations (in mM): i) 1 Mg2+, 0.5 Ca2+; ii) 1 Mg2+, 
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1 Ca2+; iii) 1Mg2+, 2 Ca2+.  After approximately 20 minutes at 35°C (i.e., once transferred 
into the 1 Mg2+, 2 Ca2+ ACSF).  
 
Patch-clamp recordings in brain slices 
Once transferred to 1 Mg2+, 2 Ca2+ ACSF,  slices were allowed to return to room 
temperature and after at least a further 40 minutes recovery time, a single slice was 
transferred to a submerged chamber and superfused with recording ACSF (containing 
(in mM): 125 NaCl, 2.4 KCl, 26 NaHCO3, 1.4 NaH2PO4, 20 D-glucose, 1 MgCl2, 2 CaCl2, 
bubbled with Carbogen).  Individual CA1 pyramidal or dentate gyrus granule neurones 
were visualised using infrared-differential interference contrast microscopy on an 
upright microscope (model BX50WI, Olympus, UK).  Glass microelectrodes for patch-
clamp were pulled from borosilicate glass capillaries (Catalogue number GC150F-7.5, 1.5 
mm OD x 0.86 mm ID, Biochrom-Harvard Apparatus Ltd, Cambridge, UK) on a vertical 
puller (model PP830, Narishige International Ltd, London UK).  Electrodes (tip 
resistance approximately 5 M ) were filled with a CsCl-based internal solution 
(containing (in mM):  CsCl 140, HEPES 5, EGTA 10, Mg-ATP 2, pH 7.4, ~290 mOsm/l).  
Patch-clamp recordings were performed using an Axopatch 1D (Molecular Devices, 
Sunyvale, CA, USA), and current signals low-pass filtered at 10 kHz then 2 kHz 
(Brownlee Precision Model 440, NeuroPhase, Santa Clara, CA, USA) during digitization 
(10 kHz; 1401plus, Cambridge Electronic Design, Limited, Cambridge, UK) and acquired 
using WinWCP (for isolated events; version 4.6.1; John Dempster, Strathclyde 
University, UK) and WinEDR (for continuous recordings; John Dempster, Strathclyde 
University, UK).  Stimulation was applied via a patch electrode filled with ACSF, placed 
extracellularly in the appropriate axon path using a square pulse constant-voltage 
stimulator (100 µs; DS2A-MkII, Digitimer Ltd, UK) triggered by WinWCP.  
 WinEDR synaptic analysis software was used for detection of spontaneous and 
miniature currents and WinWCP used to analyse identified spontaneous, miniature and 
evoked currents.  Criteria for detection of spontaneous or miniature currents was to 
remain over a threshold of 3 pA for 2 ms. Currents were inspected by eye and only 
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Field potential recordings in brain slices 
Slices were transferred as needed to a heated (30±1°C) submerged chamber and 
superfused with ACSF and allowed to recover for 1 h in the recording chamber.  A glass 
stimulating electrode (filled with ACSF, resistance ~2 MΩ) and an identical recording 
electrode (connected to an AxoClamp 1B via a 1X gain headstage) were both positioned 
in stratum radiatum of the CA1 field to obtain a dendritic excitatory postsynaptic field 
potential (fEPSP). Recordings were controlled and recorded using WinWCP software (as 
above), filtered at 10 kHz and subsequently at 3 kHz and digitized at 10 kHz via a 
micro1401 interface (Cambridge Electrical Designs, UK). Stimuli (constant voltage 10-
70V, 100 μs; model Digitimer DS2A-MkII or Grass SD9) were applied at 0.1 Hz and 
resultant fEPSPs subsequently averaged over consecutive 1-minute intervals.  
Stimulation intensity was set at approximately 30-50% of the intensity required to 
evoke a population spike or the maximum fEPSP amplitude obtained and a ≥15-minute 
stable baseline recorded.  LTP conditioning was applied at test-pulse stimulus intensity 
and consisted of 3 trains of tetani, each consisting of 20 pulses at 100 Hz, 1.5 s inter-
train interval. Following conditioning, fEPSPs were evoked at 0.1 Hz for 1 hour. 
 
Behavioural testing 
T-maze forced alternation task  
Previously reported methods, optimised for mouse, were used to assess hippocampus-
dependent learning [19]. Mice were food deprived to 90% free-feeding-weight, beginning 
2 days before the start of the habituation phase and with ad libitum access to water. 
Each mouse was handled at the start of food deprivation and throughout T-maze 
habituation for 15-20 minutes per weekday. 
 The T-maze was constructed from three arms, each measuring 50 x 8 cm with 10 
cm colourless Perspex walls and a grey floor, mounted on a table in the centre of a room 
with numerous distal visual cues, such as black and white posters on the walls. Black 
barriers were used to block the start and goal arms.  Reward consisted of a drop of 
Nestlé Carnation  condensed milk that was placed at the end of each goal arm. Arms 
were cleaned with 70% ethanol between all runs to reduce odour cues. In addition, in an 
inaccessible well a drop of reward is always present in both arms. 
 Mice received 4 days of habituation to the maze, during which time they were 
allowed to explore the maze for 5 minutes with all arms open.  During the first two days 
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of habituation, reward was scattered along the floor and in food wells to encourage 
exploratory behaviour; then restricted to only the food wells at the ends of the goal arms 
in the last two days. 
 The behavioural regime lasted for five weeks, with five days of training or testing 
per week. Initially over the first two weeks, animals received six trials which was 
increased to 12 trials in the third week; each trial consisted of a sample and choice run. 
In the sample run, one arm was blocked off. The mouse was placed at the starting point 
at the base of the T, the barrier was removed and the mouse was allowed to go to the 
available arm and given 20 s to eat a drop of reward from the food well. For the choice 
run, the mouse was immediately returned to the starting point and the barrier in the 
previously blocked arm removed. The starting barrier was then raised and the animal 
allowed to choose between the two arms but only rewarded if it chose the previously 
unvisited arm. Thus, a correct choice was scored when the mouse selected the arm not 
visited in the sample run. After the choice run, the mouse was removed from the maze 
and placed in its holding box. The location of the sample arm (left or right) was varied 
pseudorandomly across the session and mice received three left and three right 
presentations, with no more than two consecutive trials with the same sample location. 
Animals were allowed a maximum of 5 minutes to make a choice to enter a goal arm in 
both runs before a trial was aborted. If an incorrect arm was chosen during the choice 
run, the mouse was confined in the arm with no reward for 20 s and then removed from 
the maze. 
 During the first three weeks of training the choice run followed immediately after 
the sample (test) run (there was a delay of approximately 15 s between runs for 
cleaning and resetting the maze).  Data was analysed in blocks of 2 days and hence 
blocks 1-5 represent the first 2 weeks of training. 
 On the first day of the fourth week, mice received a repeat of the previous 
training sessions in order to assess retention of the task and complete the 8th block. On 
the following two weeks, longer delays (1-10 minutes) were introduced between the 
sample and choice runs to extend the time that the previous choice was to be held in 
memory. During these intervals, each animal was placed in a separate holding box. Each 
mouse received two of each of the delay periods per day, varied pseudorandomly both 
within and across days. Squads of 15-17 mice were run per day.  During training data 
are presented as blocks averaged across 2 days for each animal. For delays the four runs 
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for each delay are averaged. Response times were calculated from the time that the 
starting block was removed until the mouse made a choice of arms and all four paws had 
crossed the entry point 
 
Open field 
The open field consisted of a plastic cylinder (diameter: 47.5 cm, height 36 cm) with a 
white plastic floor. Mice were placed on the periphery of the open field floor and allowed 
to explore freely for 30 minutes. The path of each mouse was recorded using dacQUSB 
recording system (Axona, St. Albans, U.K) at a sample rate of 50 Hz. The open field was 
optically divided into a central circle and a peripheral ring, each with equal area. The 
path of the mouse was analysed offline using ImageProPlus.  Path length and dwell times 
in the periphery and centre were calculated using custom made routines written in 
Matlab R2010a (MathWorks). 
 
Light/dark box  
Analysis in the light/dark box was based on methods described by Packard et al [20]. The 
dark box measured 20 cm x 20 cm x 30 cm, with black walls, floor and lid. The light box 
measured 30 cm x 30 cm x 30 cm with a white floor and light grey walls. The boxes were 
connected by an opening in the partition between the two compartments. An overhead 
light provided bright illumination in the light box. Mice were placed in the centre of the 
light compartment facing away from the opening and then allowed to explore for a 
period of 6 minutes. Time spent in each box and the number of entries into each box 




All data analysis was carried out blind to genotype. All statistics were performed using 
Graphpad Prism 6 with appropriately designed two-tailed t-test or ANOVA.  Post hoc 
tests were only performed if a significant interaction between the independent variables 
was obtained.  Animals were considered as independent samples and, where multiple 
data were collected from an animal, these were averaged (mean) prior to pooling. Thus 
sample sizes represent the number of animals.  Unless stated otherwise, data are 
presented as mean ± SEM and differences considered significant at p<0.05. 
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Results  
Identification of two separate TauD35 transgenic lines determined using TaqMan qPCR 
Tau D35 express human Tau with the P301L mutation that causes hyperphosphylation 
of Tau [21] and was initially developed at GlaxoSmithKline as a single mouse line. 
However it became clear, as the genotypes were progressively uncoded in this blind 
study, that in some but not all types of experiments, the results from the transgenic mice 
fell clearly into two groups. In particular, a subset of mice showed a considerably higher 
density of neurofibrillary tangles at around 13 months of age than others. Moreover, in 
mice aged further, a subset of Tau mice showed a severely neurodegenerative 
phenotype, rapidly developing over about 2 weeks at 16-18 months of age, consisting of 
a hunched posture, piloerection and akinesia. This was so severe that it required these 
mice to be euthanised at this age, while others remained phenotypically normal at 24 
months. We thus retrospectively determined the transgene copy number from all of the 
TauD35 mice included in the study. 
In order to ascertain the number of transgene copies harboured by TauD35 
animals, qPCR techniques were employed. Due to the similarity of the human and 
murine Tau sequence, transgene copy number was determined solely through the 
development of a probe to the CaMKIIa promoter. Assuming an endogenous murine 
CaMKIIa copy number of two, results gathered from transgenic animals were analysed 
relative to wild type copy numbers. Two clear groups within the transgenic line were 
apparent, one with approximately twice the copy number of the other (in the order of 10 
and 5 copies respectively). Unfortunately, by the time the reason for this variability was 
uncovered, the HighTAU copy number had largely been bred out of the colony 
preventing us from increasing sample sizes in this group. The finding of this variability 
in copy number has the disadvantage of some experiments featuring only few animals 
with high copy number but the advantage is that we can at least preliminarily judge 
whether any effects of the TauP301L transgene are dose-dependent. Consequently, all 
data were pooled but with the individual copy number groups indicated in overlying 
scatter graphs. If strong trends or significant differences were seen between these lines 
then they were also analysed separately, where possible. 
The two lines are referred to here as LowTAU and HighTAU, respectively. 
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Relative protein levels are also different in the two Tau lines, especially at younger ages  
Protein levels and phosphorylation states of Tau were measured by Western blot using 
an array of antibodies (Fig 1). This further confirmed that the two Tau lines expressed 
different levels of protein in relation to their transgene copy number. Firstly, using the 
human-Tau-specific antibody HT-7, we assessed levels of the TauP301L protein. At 4 
months of age, levels of human Tau were higher in HighTAU mice than in LowTAU mice 
of the same age (p=0.01; Fig 1A). This difference was less marked at 13 months but was 
highly significant (p<0.005). As expected, there was no immunopositive bands for 
human Tau observed in samples from wild type mice.  The less pronounced difference at 
the older age is presumably because of increased Tau aggregation in the HighTAU mice 
which would be removed during initial centrifugation for Western blot [22].  We next 
used the pan-Tau antibody, DA9, which, in brain tissue from wild type animals at high 
exposure, revealed bands at ~50kDa, ~58kDa and ~64kDa, corresponding to the 3 
endogenous monomeric isoforms of mouse Tau expressed in adult mice [23-25], with small 
increases in molecular weight due to endogenous phosphorylation, when compared to 
de-phosphorylated/recombinant Tau [26].  The bands at the higher molecular weights are 
clearer when the HT-7 antibody is used to label the Sarkosyl insoluble fraction which 
represents the Tau tangles (Fig 1E). Moreover, although we cannot accurately quantify 
the protein levels in this fraction because the usual housekeeping genes are not present, 
we attempted to standardise the loading of protein between lanes to allow at least a 
qualitative comparison within ages and total protein assessed using amido black. The 
relatively strong signal of Tau in ΗighTAU mice compared to LowTAU mice supports the 
hypothesis that the apparently low level of Tau seen in the blots in Figs 1A-D is due to 
the increased deposition resulting in Tau being lost in the first stage of homogenisation 
which is the source of the P3 pellet from which the sarkosyl insoluble fraction (Fig 1E) is 
prepared.  
Finally, we assessed the phosphorylation at early (S202) and late (S396/S404) 
sites on the Tau protein using CP13 and PHF-1 antibodies, respectively [13].  A similar 
pattern of age-dependent Tau phosphorylation was seen with both CP13 and PHF-1, 
with a low level of phosphorylation present in wild type mice at all ages observed with 
both antibodies. Transgenic mice display a high level of both S202 (CP13) and 
S396/S404 (PHF-1) phosphorylated Tau when compared to wild type mice at all ages 
(Fig 1C&D).  Interestingly, while at 4 months of age transgenic mice present 
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phosphorylated Tau species between 50 and 60 kDa with little if any of the higher 
molecular weight component detectable, the larger species at around 64 kDa become 
clear in the 13-months old HighTAU mice but not until 24-months in the LowTAU mice, 
suggesting a dose and age dependent increase in this hyperphosphorylated component. 
 
Neurodegeneration and neurofibrillary tangle development 
There were notable differences in brain size of HighTAU mice at 18 months compared to 
either age-matched wild type or LowTAU mice (Fig 2). This was indicated by a reduced 
hippocampal area, thinning of the cortex and enlargement of the dorsal ventricle. 
Furthermore, cresyl violet staining revealed that there was overt neuronal loss in CA1, 
indicated by lower cell counts at both 13 months (~80% of wild type, p=0.07) and 18 
months of age (~40% of wild type, p<0.01; 2-way ANOVA interaction between age and 
genotype p=0.02; Fig 2). Similarly, there were fewer CA3 neurones in HighTAU animals, 
reflected by a significant main effect of genotype by 2-way ANOVA (p<0.01). In this case 
there was no interaction between age and genotype. We have concentrated subsequent 
analysis on the CA1 region but similar differences are seen throughout the hippocampus 
and cortex. 
Immunohistochemistry was also carried out to assess the occurrence of 
neurofibrillary tangles and the regional specificity of different stages of Tau 
phosphorylation. Similar antibodies were employed to the Western blot experiments 
above, after testing specificity of antibodies in this context. Antibodies needed to be 
specific for Tau, recognise common pathological epitopes found in both human patients 
as well as other mouse models and also cover a wide range of pathological species (see 
methods and for review [13]). To this end, a range of both commercial antibodies and 
non-commercial antibodies (kindly provided by Peter Davies, Albert Einstein College of 
Medicine, USA) were chosen, including: HT7 (human Tau), as well as AT8, CP13 (both 
markers for early Tau phosphorylation [14, 15, 27]) and MC1 (misfolded human Tau [16, 17]) 
and PHF-1 (later Tau phosphorylation [15]). A distinct pattern of immunofluorescence 
was observed in both CA3 and CA1 pyramidal neurones of the hippocampus, granule 
cells of the dentate gyrus, cells within the hilus and also the surrounding cortex (Fig 
3Ai).  Mossy fibre axonal projections from dentate gyrus to CA3 were particularly 
prominent (Fig 3Ai and Aii).  The tangle-like structure of the Tau immunofluorescence 
were detected within the soma of neurones using confocal imaging (Fig 3Aiii). 
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Interestingly, once separated, it was clear that the 2.5-fold difference in Tau 
protein levels seen at 4 months between the HighTAU and LowTAU lines translated into 
considerable differences in the occurrence of neurofibrillary tangles by 13 months of age 
(Fig 3B&C). The density of tangle-like structures labelled with antibodies to all the 
proteins listed above by 13 months was around 100-fold higher in HighTAU than in 
LowTAU mice in the CA1 region (Fig3Bi). This is consistent with the effects seen above 
in the Western blot analysis, particularly in the Sarkosyl insoluble fraction. By 24 
months, by which time neurodegeneration has resulted in the culling of all the HighTAU 
mice, the LowTAU mice eventually reach the high density of tangle-like staining that is 
seen at 13 months in the HighTAU mice (Fig 3Bi).  The increase in the number of tangles 
remained evident when normalised to the cell density (Fig 3Bii). 
 
Microglia in Tau mice 
We have previously reported that the same Tau mice used in the present study showed 
no difference in expression of Iba1 (Aif1) or a range of other microglial genes at young 
ages, even at 8 months as neurofibrillary tangles start to appear in HighTAU mice [1]. 
This suggested that there was little or no proliferation or activation of microglia up to 
this age. Here we examine distribution and phenotype of microglia in Tau mice in more 
detail using immunohistochemistry (Fig 4). Firstly, at 4 months of age, we confirm that 
there is no proliferation or activation of microglia, as measured by counting Iba1 and 
CD68 positive microglia, respectively, in the CA1 region in fixed sections of hippocampus 
in either LowTAU or HighTAU mice. By 13 months, while the wild type mice and lowTAU 
mice show similar age-related increases in both proliferation and activation (see also 
wild type mice in [11]), HighTau mice show much greater changes. At this age HighTAU 
mice show a heavy load of neurofibrillary tangles and the start of neurodegeneration 
and there is a significant proliferation of microglia, (two-way ANOVA genotype x region 
interaction p<0.0001). This was especially strong in the stratum lacunosum moleculare 
(SLM, 3 fold change compared to WT (p<0.0001) but also with significant increases in all 
other layers (SO ~2-fold increase, p<0.001; SP, SR ~65% increase p<0.05).  Moreover, 
activation in HighTAU mice is also increased (two-way ANOVA genotype x region 
interaction p<0.005) and again the increase in SLM was particularly strong (~7 fold 
p<0.0001) and SO also showing a significant increase (2.7 fold, p<0.01). However, this 
result is difficult to interpret as the proportion of activated microglia in WT mice was 
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very variable between individual mice, possibly relating to this age being the time when 
increases in activation and proliferation are occurring in all genotypes [11].  Moreover, 
the number of HighTAU mice and the number of activated microglia per section is very 
low, leading to potential sampling artefacts so that only large changes could be reliably 
detected.  Similar results were obtained in other hippocampal regions. 
Having established these initial changes, we proceeded to study the latest stages 
of pathology available in these mice.  LowTAU mice were aged to 24 months but 
HighTAU mice could not be aged this far because the strong neurodegenerative 
phenotype that occurs at 17-18 months is considered end stage. As outlined above, at 
this stage there is considerable neurodegeneration.  We thus compared these two 
groups of mice in detail, also referring back to the earlier stages described above. 
The 24-month-old LowTAU mice have a similar density of tangles to the 13-
month-old HighTAU mice (Fig 3) but, at this stage, they have no measurable 
neurodegeneration (Fig 2).  Proliferation of microglia was evident at around 2-fold in 
the 24-month-old LowTAU mice compared to WT mice but only in the stratum 
lacunosum-moleculare and not in other CA1 regions (Fig 4F). Moreover activation 
(measured by CD68 positive microglia), was also increased by almost 10-fold in the SLM. 
Hence the SLM showed a very similar microglial response at this stage to the HighTAU 
mice at the equivalent stage. Interestingly there was a strong trend to show increased 
proliferation also in the other CA1 regions despite lack of proliferation at this stage in 
the 24 month old LowTAU mice suggesting that activation may precede proliferation in 
these mice. 
In contrast, in the strongly neurodegenerating 17-18-month-old HighTAU mice, 
microglia both proliferate and activate across all CA1 fields (Fig 4E).  
 
Synaptic transmission in TauD35 mice 
To study the early effects of the Tau transgene on neuronal function, whole cell voltage 
clamp recordings were performed. Again, retrospective genotyping was used to 
determine transgene copy number and data are presented as both composite mean for 
all Tau animals and for separated LowTAU and HighTAU mice. 
 Excitatory postsynaptic currents (EPSCs) were recorded from CA1 pyramidal 
neurones using patch clamp (Fig5Ai) and were electrically and pharmacologically 
isolated in the presence of the GABAA receptor antagonist gabazine (6µM).  While there 
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an age-dependent increase in mean frequency of spontaneous EPSCs in cells recorded 
from slices of 13-month-old wild type animals, compared to those of 4-month-old 
animals, there was no significant difference in frequency, amplitude or decay time 
constant (Figs 5Aii-iv) between the genotypes at either age.  In cells from the younger 
group, 1 μΜ tetrodotoxin was added to isolate action potential-independent 
neurotransmission miniature EPSCs.  A one-way ANOVA revealed an increase in 
frequency in the transgenic mice (main effect of genotype p<0.05); Tukey corrected post 
hoc tests revealed a significant difference between wild type and HighTAU mice (p<0.05) 
and very near significance between LowTAU and HighTAU mice (p=0.053; Fig 5Aii).  
While there was no difference in miniature EPSC amplitudes between genotypes (Fig 
5Aiii), the  decay time constant was significantly different (one-way ANOVA, p<0.05) and 
a Tukey post hoc test revealed a significant difference between LowTAU and HighTAU 
mice (p<0.05; Fig 5Aiv, possibly reflecting a change in receptor subtype and/or cell 
geometry). Hence, while action potential-mediated activity and the resulting release of 
glutamate appeared to be unchanged, miniature synaptic activity was increased in the 
younger age group in the HighTAU mice compared to LowTAU or wild type mice.  
 We next examined potential changes in probability of glutamate release by 
applying pairs of stimuli to analyse paired pulse ratios (amplitude of second response 
over first) from Schaffer collateral synapses onto CA1 pyramidal neurones (Fig 5Bi).  As 
expected, synapses from wild type animals displayed paired-pulse facilitation 
(indicating a low probability of glutamate release), that decreased towards no change or 
paired-pulse depression at longer intervals.  At 4 months of age there was no significant 
difference between transgenic mice and wild type mice regardless of copy number.  At 
13 months of age, post hoc genotyping revealed only LowTAU mice in this group.  There 
were no differences in paired-pulse ratio at intervals between 25 and 800 ms, while at 
this age, the transgenic mice, despite having a LowTAU copy number, showed a 
significant depression at 1500ms compared to the wild type mice (p<0.001; Fig 5Biii). As 
expected wild type mice showed little if any interaction between the first and second 
response at this long interval. This suggests an increase in an inhibitory metabotropic 
autoreceptor or heterosynaptic connection in the transgenic animal. 
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Magnitude of long-term potentiation is normal in Tau mice but locus of expression changes 
with age 
Longer term synaptic plasticity was studied using extracellular field potentials recorded 
from stratum radiatum of CA1 in response to stimulation applied to the Schaffer 
collaterals (axons from CA3 neurones) in slices prepared from mice aged 4 to 24 
months.  Initially, input-output relationships were determined by applying increasing 
voltage pulses (Fig 6A).  There were no significant differences in the field EPSP slopes 
recorded between the genotypes at any age. Similar to the patch clamp recordings, 
paired-pulse ratios did not differ between the genotypes (Fig 6B).  Moreover, the 
magnitude of LTP (mean of responses recorded over the last 10 minutes compared to 
baseline) induced by a moderate tetanic stimulus did not differ between the genotypes 
at any age (Fig 6C&D).  However, paired-pulse ratios recorded during the time course of 
the LTP experiment did differ.  In slices from both wild type and Tau mice, the paired-
pulse ratio measured at different times after induction of LTP compared to baseline 
showed the expected transient decrease during post tetanic potentiation (no significant 
difference between genotypes at any age, data not shown).  While paired-pulse ratios in 
wild type slices returned to baseline as expected, those from Tau slices tended to remain 
lower than baseline (Fig 6C&E, two-way ANOVA, main effect of genotype, p<0.01). There 
was no significant effect of age nor an interaction between age and genotype.. This 
suggested that the locus of LTP induction may have a presynaptic component in the 
transgenic mice. As the magnitude of LTP was unchanged this may suggest a 
compensation between pre- and postsynaptic changes. 
 
Mutant Tau mice do not show cognitive changes in hippocampus-dependent learning at 12 
months of age 
The hippocampus-dependent forced-alternation T-maze task was used to assess 
cognition in 12-month-old TauD35 mice (Fig 7A; mice used subsequently for 
electrophysiology or immunohistochemistry). As outlined in detail in the methods, the 
test consisted of a sample run followed immediately by a choice run. For the sample run 
one arm of the T was blocked off so that the mouse was forced to turn in one direction 
where they received a food reward. This was then followed by a choice run in which the 
both arms were open, giving them a free choice of turning left or right; the correct arm 
(where a food reward was then available) was the opposite arm from the sample run.  
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/420398doi: bioRxiv preprint first posted online Sep. 17, 2018; 
Joel et al 2018 bioRxiv preprint v2 
Page 22 of 47 
Two mice, determined post hoc to be HighTAU mice, are reported separately from the 
LowTAU mice (n=9). 
TauD35 mice started training at similar levels to wild type mice, both improving 
to ~90% over the training days (Fig 7Ai).  Transgene copy number did not show any 
obvious differences to the outcome of the task during the training period.  When the 
mice were challenged with delays between sample and choice runs there were no 
significant differences between genotypes, although surprisingly the two HighTAU mice 
tended to improve their performance with increased delays while both wild type and 
LowTAU mice showed a decrement, as expected (Fig 7Aii). However, a clear difference 
between the HighTAU mice and both the wild type and LowTAU mice was the rate of 
response in the first (sample) run of each trial (Fig 7Aiii).  The wild type and LowTAU 
mice explored the maze, taking 5 to 20 s from being placed in the maze until all 4 feet 
were within the destination arm. In contrast, both HighTAU mice ran rapidly through the 
maze with response times starting at about 5 s but reducing to 2 s from the third block 
of the training period onwards. Although the sample size is small, this was consistent for 
both HighTAU mice in all the subsequent trials, including the delay trials, suggesting a 
lack of interaction with the novel environment or a behavioural disinhibition, similar to 
symptoms in a subgroup of frontotemporal dementia patients [28]. In the choice trial 
there was no difference in response time between genotypes with all groups responding 
within about 5 seconds (Fig 7Aiv). 
Unfortunately, the number of HighTAU mice was so low that no firm conclusions 
can be made about this potentially interesting behavioural difference but the 
consistency between the two mice flags an interesting point to be investigated in future 
studies. However, it is clear that, despite a substantial load of neurofibrillary tangles and, 
in the case of the HighTAU mice, a decrease in cell number, neither the HighTAU nor 
LowTAU mice appear to have any learning deficit in the forced T-maze. 
 We proceeded to test whether these possible behavioural changes reflected a 
change in locomotor activity or anxiety-like behaviours in the HighTAU mice (Fig 7B&C). 
In an open field arena, while there were no differences in the total path lengths between 
genotypes (Fig 7Bi), the pattern of activity was again very different for HighTAU mice.  
Both wild types and LowTAU mice decreased their total exploratory activity over time, 
while HighTAU mice maintained a constant level of exploration throughout the test 
period (Fig 7Bii&iii). Furthermore, the time they spent in the centre of the arena did not 
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increase significantly over time (Fig 7Biv). Although one mouse came close to wild type 
levels in the final 5-minute block of the test period, the other remained largely on the 
edge of the arena through all trials, a behaviour that would generally be associated with 
anxiety. 
No significant differences were seen in the light dark box (Fig 7C) when 
genotypes were considered as independent groups and tested by ANOVA although there 
was a strong trend for the Tau mice to take longer to enter the dark box (one-way 
ANOVA, p=0.06). Consistent with this a tendency was also observed for the transgenic 
mice to stay in the light for longer than the wild type mice and this was dose dependent 
showing a significant correlation to Tau copy number (p=0.05). In contrast to the open 
field result this would suggest a decrease in anxiety. 
Together, these data indicate that, despite a heavy neurofibrillary tangle load and, 
in the case of HighTAU mice, initial neurodegeneration, there is no learning deficit 
measurable with the T-maze. Possible behavioural changes in habituation and anxiety 
particularly in the HighTAU mice would need further investigation but again would be 
compatible with a lack of exploratory interaction with the environment rather than 
specific effects of anxiety. 
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Discussion 
TauD35 mice express human Tau harbouring the P301L mutation under the CaMKIIa 
promoter, which directs expression to glutamatergic cells in the forebrain (avoiding 
expression in the spinal cord or peripheral nervous system). Moreover, the distribution 
of CaMKIIa in the brain is similar to Tau making this a very suitable promoter [29]. 
The P301L mutation causes frontotemporal dementia with parkinsonism linked 
to chromosome 17 in humans but here we were also interested in considering the role of 
neurofibrillary tangles in all forms of dementia, including Alzheimer’s disease. 
Understanding the interactions of Aβ and Tau in the development of Alzheimer’s disease 
is complicated by the lack of animal models that display neurofibrillary tangles and 
neurodegeneration dependent on rising Aβ, rather than due to mutations in Tau. While 
expressing mutated human Tau is useful for understanding the link between 
neurofibrillary tangles and neurodegeneration, it bypasses the proposed link between 
the Aβ and Tau proteins [30]. However, this is the best approach available for studying 
the effects of neurofibrillary tangles on the various functional aspects of disease 
progression. Previous studies have described a range of mice with Tau mutations but, in 
general, these models have progressed rapidly, reaching neurodegeneration at relatively 
young ages (see Alzheimer’s Disease Research Models | Alzforum. Retrieved 14 June 
2018 from https://www.alzforum.org/research-models/alzheimers-disease). In fact, a 
popular model, rTg4510, harbours the same mutation controlled by the same promoter 
but including a tetracyclineoperon–responsive element allowing suppression of the 
transgene. This is a rapid model that has increasing tangle load from 4 months of age 
and substantial neurodegeneration from about 5 months onwards [3]. Moreover, spatial 
memory deficits are seen even earlier from around 2 months of age in these mice [3, 31]. 
However, in humans, particularly in Alzheimer’s disease, the cognitive effects of Tau 
pathology and neurodegeneration are usually seen in relatively old age. Hence, the more 
slowly progressing model used here allows the influence of age to be considered versus 
the rate of pathology development. This is particularly the case when comparison of the 
LowTAU mice at 24 months to the HighTAU mice at 13 months at which ages their 
neurofibrillary tangle development is similar. What is perhaps most noticeable in these 
results is that, even with a heavy neurofibrillary tangle load and modest 
neurodegeneration seen at 13 months of age in HighTAU mice, there is little if any 
learning deficit, although some behavioural changes may be evident in these slowly 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/420398doi: bioRxiv preprint first posted online Sep. 17, 2018; 
Joel et al 2018 bioRxiv preprint v2 
Page 25 of 47 
developing models. This is similar to the human condition, in which the diagnosis of the 
disease only occurs after considerable brain tissue is lost [32]. However, it is interesting 
to note that the behavioural changes seen, seem to be a lack of adaptation and 
interaction with the environment which may be relevant to cognitive effects in the more 
complex tasks of the human experience. 
 
Tau overexpression, phosphorylation and pathology 
Phosphorylated tau is detected in both LowTAU and HighTAU animals at 4 months of 
age and some of human Tau is insoluble in sarkosyl. We have previously shown in 
TauD35 mice that rare neurofibrillary tangles could be detected in 1 out of 4 mice at 4 
months and an increasing tangle load in all mice at 8 months [1]. These mice have since 
been established to be HighTAU.  In the present study aggregates are detectable by 
immunohistochemistry at 13 months of age in both groups. However, LowTAU animals 
display very few neurofibrillary tangles, along with a small decrease in the amount of 
phosphorylated protein compared to 4 months. In contrast, HighTAU animals display a 
heavy neurofibrillary tangle load at 13 months of age, corresponding to the appearance 
of insoluble Tau migrating at 64kDa, despite an overall decrease in phosphorylated Tau 
species detected by Western blot, owing to the loss of neurofibrillary tangles during 
homogenate sample preparation. This situation is mirrored in LowTAU animals of 24 
months of age (Fig 1). 
The relatively small increase in mutated human tau protein expressed in 
HighTAU mice (~2.5 fold, as assessed at 4 months, Fig 1A, before substantial 
development of tangles) compared to their LowTAU counterparts was seen to result in a 
much greater difference in the timing and extent of tau pathology development. This was 
particularly evident at 13 months of age, when LowTAU mice were seen to display only 
neurofibrillary tangles within the hippocampus, compared to the extensive spread 
observed in HighTAU animals. At this age the ratio of neurofibrillary tangles within the 
CA1 region of the hippocampus in HighTAU was ~60 times the ratio of neurofibrillary 
tangles calculated in LowTAU animals in the same region (Fig 2Bii). This relationship 
between protein level and neurofibrillary tangle development has been observed 
previously [3], suggesting that not only the mutation but the overall concentration of 
protein may be important in aggregation initiation. It is also an important observation in 
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terms of the relevance of different overexpression models, including normal Tau protein 
[25, 33], in which the concentration of Tau may be a pathological factor in itself. 
 
Pathology and microglial proliferation 
We have previously shown in mice with mutations in the Αβ pathway that the 
expression of microglial genes is closely related to plaque pathology, while this 
relationship is much weaker when compared to neurofibrillary tangle load in Tau mice 
[1]. Here we have used immunohistochemistry to study the phosphorylation of Tau and 
eventual misfolding into neurofibrillary tangles in much more detail and compared this 
to the proliferation and activation of microglia. In the TauD35 mice, although the 
detection of Tau pathology is low but clear by 8 months of age in HighTAU mice, our 
previous gene expression study shows no change in expression of either Iba1 or CD68 at 
this age [1]. Here we show with immunochemistry that also as tangles first appear in the 
13-month-old LowTAU mice, that microglia are apparently unchanged but that, with the 
greater tangle load at this age in the HighTAU mice, proliferation is the main effect. CD68 
is clearly expressed throughout the hippocampal layers once the neurodegenerative 
phenotype is fully developed in the HighTAU mice at 18 months of age. Increased CD68 
expression is suggested to relate to an increasingly phagocytotic phenotype and appears 
to coincide with cell loss in these mice. This widespread microglial activation may be 
specifically related to the removal of damaged neurones. In contrast, at the oldest age of 
LowTAU mice, where no neurodegeneration is measurable, activation of microglia is 
also present and is particularly strong in the stratum lacunosum moleculare, although 
there is a tendency to activation in other regions. The SLM is the synaptic zone for the 
entorhinal cortex inputs via the temporoammonic pathway. Initially, as synapses are 
altered and particular axons become dysfunctional, removal of such dysfunctional axons 
could be protective to the ongoing network activity. This is, however, a one-way process 
and eventually the network would not continue effectively once substantial cell loss has 
occurred. Interestingly, although very delayed compared to rTg4510 mice, the 
neurodegenerative phenotype once it begins in HighTAU mice, is rapid. This rapidly 
developing neurodegenerative morbid phenotype makes cognitive testing impossible. It 
is interesting to note however that the lowTAU mice develop a substantial tangle load by 
24 months (similar to 13 months highTAU mice) but feature a much more robust 
activation of the microglia at this stage but no detectable neurodegeneration. This may 
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suggest that the microglia can protect against neurodegeneration more effectively if the 
Tau pathology develops more slowly. 
 
Synaptic transmission and plasticity 
In mice with rising Αβ, we have previously reported that at 2 months in the CA1 region, 
even before the first plaque deposition, there is a complete loss of spontaneous action 
potential mediated release [34]. Moreover, in evoked transmission in the Schaffer 
collateral pathway, an increase in glutamate release probability was observed in the Αβ 
mice compared to wild type mice at these early stages. These changes persisted 
throughout pathology development [11]. In contrast, the TauD35 mice investigated here 
showed only very subtle changes in synaptic transmission which did not persist as 
tangle load developed. Perhaps not surprisingly, considering the minimal effects on 
basal synaptic transmission in Tau mice, LTP was not affected, although the locus of 
expression may have gained a presynaptic component in the Tau mice, suggesting 
homeostatic changes between pre- and postsynaptic compartments. 
The effects on synaptic plasticity were rather more marked in Αβ mice, with an 
early enhancement at 2 months, followed by an almost complete loss of LTP when 
tetanic stimulation was used. Interestingly this was dependent on the stimulation 
paradigm but like the synaptic transmission changes persisted throughout pathology 
development. Hence, even though there is no neurodegeneration in the Αβ mice, the 
effects on synaptic transmission are stronger, suggesting that early physiological 
changes occur due to low Αβ levels in the neuropil, whereas considerable changes in Tau 
phosphorylation or even presence of a heavy tangle load have little effect on 
physiological function but rather relate directly to the death of neurones. 
 
Behaviour 
Neither the Tau nor the Αβ mice showed cognitive deficits at 12 months of age, despite a 
heavy neurofibrillary tangle or plaque load respectively. At some levels this was 
surprising, particularly in the HighTAU mice which, unlike the LowTAU mice have 
substantial Tau pathology and are starting to show neuronal loss at this age. However, 
this is less surprising when the human disease is considered. Fox et al [32, 35] reported 
that people with familial genes for Alzheimer’s disease have already lost 20% of the 
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hippocampus before they start to show symptoms, confirming that the brain is 
extremely good at compensating for change. 
While both Tau and Αβ mice performed at similar levels as their wild type 
littermates in the T-maze, there were differences in motor activity and anxiety related 
behaviours both compared to wild type mice and comparing the different pathologies. 
This was reflected in both the T-maze, where HighTAU mice completed the sample run 
in under a quarter of the time of either wild types or LowTAU mice, and also the open 
field arena, where HighTAU mice failed to habituate to the arena but continued being 
highly active at a time when wild type mice had decreased their activity. In contrast, the 
Αβ mice [11] were slower to perform the T-maze task or failed to do so altogether and 
were less active in the open field than the wild type mice. Surprisingly, when plaque load 
was high at 12 months, they showed a tendency to retain memory for longer than the 
wild type mice. 
When tests of anxiety were performed the Tau and Αβ mice initially both 
appeared to be more anxious, staying on the periphery of the open field.  However, while 
this interpretation was confirmed in further tests on the Αβ mice, the interpretation of 
the behaviour of the Tau mice was less clear. In the light/dark box anxiety would be 
indicated by staying in the dark which was the result for the Αβ mice but the Tau mice 
stayed in the light more than wild type mice and moreover this seemed to be dose 
dependent in relation to copy number. In combination these behaviours suggest that 
there is certainly a behavioural change in the Tau mice which may indicate a lack of 
interaction with their environment.  
The lack of memory deficits and overall subtlety of the behavioural changes 
reported here for both the Tau and Αβ mice, even at stages of advanced pathology but 
without gross neurodegeneration, is consistent with previous findings for the present 
Αβ model [36-39] and in other Αβ models [for reviews, see 40, 41]. Deficits are seen early in the 
rTg4510 mouse as neurodegeneration begins [2, 3, 31]. The results in these more slowly 
developing models is however more consistent with the human condition, where, by the 
time sufficient deficit is evident for diagnosis, there is already a substantial reduction in 
hippocampal volume of up to 20% [32, 35]. It is notable that in the rTg4510 mice the 
neurodegeneration occurs over several months (for example between 5 and 16 months 
[2]) with behavioural testing up to 12 months [31]), although this varies considerably 
between different studies [2, 3, 31]. In the much older TauD35 model reported here the 
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initial tendency to neurodegeneration at 13 months in HighTAU mice does not result in 
any measurable cognitive deficit, whereas substantial neurodegeneration sets in 
relatively rapidly with a strong morbid phenotype developing over about 2 weeks at 
ages between 16.5 and 19 months preventing behavioural testing. 
 Given that Αβ mouse models are not a complete model of AD, i.e. lacking 
neurofibrillary tangle formation and neurodegeneration, which more faithfully correlate 
with cognitive decline, they should be considered as models of the preclinical disease, 
when Αβ is first deposited.  The Tau models may make better models of end-stages of 
disease, when neurodegeneration and neurofibrillary tangle predominate the pathology.  
However, unless bypassed by mutations in Tau, to date, no animal model reliably offers 
the crucial link between rising Aβ and neurofibrillary tangles that are required to 
understand the full progression of the disease. It is interesting to note how well the 
mammalian brain can compensate and, particularly in the Tau mice how little apparent 
phenotype is present in terms of cognition even once neurodegeneration is under way. 
 
Conclusion:  
Given that Αβ mouse models are not a complete model of AD, i.e. lacking neurofibrillary 
tangle formation and neurodegeneration, which more faithfully correlate with cognitive 
decline, they should be considered as models of the preclinical disease, when Αβ is first 
deposited.  The Tau models may make better models of end-stages of disease, when 
neurodegeneration and neurofibrillary tangle predominate the pathology.  However, 
unless bypassed by mutations in Tau, to date, no animal model reliably offers the crucial 
link between rising Aβ and neurofibrillary tangles that are required to understand the 
full progression of the disease. It is interesting to note how well the mammalian brain 
can compensate and, particularly in the Tau mice, how little apparent phenotype is 
present in terms of cognition even once neurodegeneration is under way. The 
comparison of Aβ and Tau models brings up some interesting contrasts, suggesting that 
the levels of soluble Aβ in the general neuropil, independent of the position or even 
presence of plaques, has substantial effects, particularly on neurotransmitter release 
from glutamatergic synaptic transmission. The presence of plaques does not greatly 
change this, although it causes a strong immune response, possibly related to the 
removal of dystrophic neurites. Such dystrophic neurites only occur locally in and 
around the plaque, with synaptic loss having been reported to decrease with distance 
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from the plaques [42, 43].  The percentage area covered by plaques is small, even when the 
plaque load is heavy and hence, relative to the total number of synapses, only relatively 
few will be directly lost due to proximity to plaques. In contrast, although the 
development of Tau tangles is associated with neurodegeneration, generalised effects on 
synaptic responses in the wider network are more subtle until a period of rapid 
deterioration occurs as neurodegeneration reaches a critical stage. We suggest that this 
may relate to the Tau pathology causing loss of whole axons which eventually will cause 
network disruption in contrast to the localised effects of plaques but that in the human 
disease, the localised synaptic damage caused by plaques may trigger the 
phosphorylation and eventual dissociation of Tau from the microtubules. 
 
  
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/420398doi: bioRxiv preprint first posted online Sep. 17, 2018; 
Joel et al 2018 bioRxiv preprint v2 
Page 31 of 47 
Competing interests 
The authors declare no competing interests. 
Funding 
GlaxoSmithKline (FAE); EPSRC Case Studentship with GSK for ZJ (FAE); UCL 
International Studentship for WL (FAE); ARUK and UCL ARUK Network (FAE, DMC, 
DAS); MRC (FAE) (KJS); BBSRC for LM (FC); Fondation Leducq (KJS); Multiple Sclerosis 
Society UK (KJS); National Multiple Sclerosis Society, USA (KJS); Rosetrees Trust (KJS) 
Authors' contributions 
ZJ Performed and analysed western blots, Tau immunohistochemistry, LTP and patch 
clamp electrophysiology and behaviour, created figures and commented on draft 
manuscript.  PB performed LTP experiments and microglial immunohistological staining 
and counting at 24 months of age and commented on draft manuscript.  WL performed 
immunohistological staining and counting of microglia at 4 and 13 months of age and 
commented on draft manuscript.  CH and MR performed immunohistologcal staining 
and counting of microglia at 18 months of age and commented on draft manuscript. KY 
performed LTP experiments at 24 months of age.  AN and ES performed LTP 
experiments.  RD trained and supervised students for microglial staining. LM supervised 
behavioural experiments.  RS performed genotyping and supervised students.  SM 
designed protocol to determine Tau transgene copy number and performed genotyping.  
KS supervised immunohistochemistry.  JCR created mice and commented on draft 
manuscript.  FC designed and supervised behavioural experiments and commented on 
draft manuscript.  DAS supervised molecular biology and histochemisty.  DMC 
performed electrophysiology, supervised all experiments, wrote first draft of 
manuscript, created figures, performed all statistical analyses, edited and finalised 
manuscript.  FAE obtained funding, designed and coordinated experiments, edited and 
finalised manuscript. All authors read and approved the final manuscript 
Acknowledgements 
The authors thank Tammaryn Lashley for histological advice and the Maria 
Fitzgerald/Steve Hunt laboratories for use of equipment. 
  
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/420398doi: bioRxiv preprint first posted online Sep. 17, 2018; 
Joel et al 2018 bioRxiv preprint v2 
Page 32 of 47 
References 
1. Matarin M, Salih DA, Yasvoina M, et al. A genome-wide gene-expression analysis and 
database in transgenic mice during development of amyloid or tau pathology. Cell 
Rep 2015;10: 633-44. DOI:10.1016/j.celrep.2014.12.041. 
2. Ramsden M, Kotilinek L, Forster C, et al. Age-dependent neurofibrillary tangle 
formation, neuron loss, and memory impairment in a mouse model of human 
tauopathy (P301L). J Neurosci 2005;25: 10637-47. DOI:10.1523/JNEUROSCI.3279-
05.2005. 
3. Santacruz K, Lewis J, Spires T, et al. Tau suppression in a neurodegenerative mouse 
model improves memory function. Science 2005;309: 476-81. 
DOI:10.1126/science.1113694. 
4. Yoshiyama Y, Higuchi M, Zhang B, et al. Synapse loss and microglial activation 
precede tangles in a P301S tauopathy mouse model. Neuron 2007;53: 337-51. 
DOI:10.1016/j.neuron.2007.01.010. 
5. Sydow A, Van der Jeugd A, Zheng F, et al. Tau-induced defects in synaptic plasticity, 
learning, and memory are reversible in transgenic mice after switching off the toxic 
Tau mutant. J Neurosci 2011;31: 2511-25. DOI:10.1523/JNEUROSCI.5245-10.2011. 
6. Sydow A, Van der Jeugd A, Zheng F, et al. Reversibility of Tau-related cognitive 
defects in a regulatable FTD mouse model. J Mol Neurosci 2011;45: 432-7. 
DOI:10.1007/s12031-011-9604-5. 
7. Spires-Jones TL, Hyman BT. The intersection of amyloid beta and tau at synapses in 
Alzheimer's disease. Neuron 2014;82: 756-71. DOI:10.1016/j.neuron.2014.05.004. 
8. de Calignon A, Polydoro M, Suarez-Calvet M, et al. Propagation of tau pathology in a 
model of early Alzheimer's disease. Neuron 2012;73: 685-97. 
DOI:10.1016/j.neuron.2011.11.033. 
9. Spires-Jones TL, de Calignon A, Matsui T, et al. In vivo imaging reveals dissociation 
between caspase activation and acute neuronal death in tangle-bearing neurons. J 
Neurosci 2008;28: 862-7. DOI:10.1523/JNEUROSCI.3072-08.2008. 
10. Wang JZ, Wang ZH, Tian Q. Tau hyperphosphorylation induces apoptotic escape and 
triggers neurodegeneration in Alzheimer's disease. Neurosci Bull 2014;30: 359-66. 
DOI:10.1007/s12264-013-1415-y. 
11. Medawar E, Benway TA, Liu W, et al. Effects of rising amyloid beta on hippocampal 
synaptic transmission, microglial response and cognition in APPSwe/PSEN1M146V 
transgenic mice. bioRxiv 2018;420349:  DOI:10.1101/420349. 
12. Taylor SC, Berkelman T, Yadav G, Hammond M. A defined methodology for reliable 
quantification of Western blot data. Mol Biotechnol 2013;55: 217-26. 
DOI:10.1007/s12033-013-9672-6. 
13. Petry FR, Pelletier J, Bretteville A, et al. Specificity of anti-tau antibodies when 
analyzing mice models of Alzheimer's disease: problems and solutions. PLoS One 
2014;9: e94251. DOI:10.1371/journal.pone.0094251. 
14. Kimura T, Ono T, Takamatsu J, et al. Sequential changes of tau-site-specific 
phosphorylation during development of paired helical filaments. Dementia 1996;7: 
177-81.  
15. Su JH, Cummings BJ, Cotman CW. Early phosphorylation of tau in Alzheimer's 
disease occurs at Ser-202 and is preferentially located within neurites. Neuroreport 
1994;5: 2358-62.  
16. Jicha GA, Bowser R, Kazam IG, Davies P. Alz-50 and MC-1, a new monoclonal 
antibody raised to paired helical filaments, recognize conformational epitopes on 
recombinant tau. J Neurosci Res 1997;48: 128-32.  
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/420398doi: bioRxiv preprint first posted online Sep. 17, 2018; 
Joel et al 2018 bioRxiv preprint v2 
Page 33 of 47 
17. Weaver CL, Espinoza M, Kress Y, Davies P. Conformational change as one of the 
earliest alterations of tau in Alzheimer's disease. Neurobiol Aging 2000;21: 719-27.  
18. Imai Y, Ibata I, Ito D, Ohsawa K, Kohsaka S. A novel gene iba1 in the major 
histocompatibility complex class III region encoding an EF hand protein expressed 
in a monocytic lineage. Biochem Biophys Res Commun 1996;224: 855-62. 
DOI:10.1006/bbrc.1996.1112. 
19. Cacucci F, Yi M, Wills TJ, Chapman P, O'Keefe J. Place cell firing correlates with 
memory deficits and amyloid plaque burden in Tg2576 Alzheimer mouse model. 
Proc Natl Acad Sci U S A 2008;105: 7863-8. DOI:10.1073/pnas.0802908105. 
20. Packard MG, Introini-Collison I, McGaugh JL. Stria terminalis lesions attenuate 
memory enhancement produced by intracaudate nucleus injections of 
oxotremorine. Neurobiol Learn Mem 1996;65: 278-82. 10.1006/nlme.1996.0033. 
21. Alonso Adel C, Mederlyova A, Novak M, Grundke-Iqbal I, Iqbal K. Promotion of 
hyperphosphorylation by frontotemporal dementia tau mutations. The Journal of 
biological chemistry 2004;279: 34873-81. DOI:10.1074/jbc.M405131200. 
22. Berger Z, Roder H, Hanna A, et al. Accumulation of pathological tau species and 
memory loss in a conditional model of tauopathy. J Neurosci 2007;27: 3650-62. 
DOI:10.1523/JNEUROSCI.0587-07.2007. 
23. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, 
phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 
2000;33: 95-130.  
24. Liu C, Gotz J. Profiling murine tau with 0N, 1N and 2N isoform-specific antibodies in 
brain and peripheral organs reveals distinct subcellular localization, with the 1N 
isoform being enriched in the nucleus. PLoS One 2013;8: e84849. 
DOI:10.1371/journal.pone.0084849. 
25. Adams SJ, Crook RJ, Deture M, et al. Overexpression of wild-type murine tau results 
in progressive tauopathy and neurodegeneration. Am J Pathol 2009;175: 1598-609. 
DOI:10.2353/ajpath.2009.090462. 
26. Hanger DP, Gibb GM, de Silva R, et al. The complex relationship between soluble and 
insoluble tau in tauopathies revealed by efficient dephosphorylation and specific 
antibodies. FEBS Lett 2002;531: 538-42.  
27. Bertrand J, Plouffe V, Senechal P, Leclerc N. The pattern of human tau 
phosphorylation is the result of priming and feedback events in primary 
hippocampal neurons. Neuroscience 2010;168: 323-34. 
DOI:10.1016/j.neuroscience.2010.04.009. 
28. Snowden JS, Bathgate D, Varma A, Blackshaw A, Gibbons ZC, Neary D. Distinct 
behavioural profiles in frontotemporal dementia and semantic dementia. J Neurol 
Neurosurg Psychiatry 2001;70: 323-32.  
29. Lein ES, Hawrylycz MJ, Ao N, et al. Genome-wide atlas of gene expression in the adult 
mouse brain. Nature 2007;445: 168-76. DOI:10.1038/nature05453. 
30. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO 
Mol Med 2016;8: 595-608. DOI:10.15252/emmm.201606210. 
31. Blackmore T, Meftah S, Murray TK, et al. Tracking progressive pathological and 
functional decline in the rTg4510 mouse model of tauopathy. Alzheimers Res Ther 
2017;9: 77. DOI:10.1186/s13195-017-0306-2. 
32. Fox NC, Warrington EK, Freeborough PA, et al. Presymptomatic hippocampal 
atrophy in Alzheimer's disease. A longitudinal MRI study. Brain : a journal of 
neurology 1996;119 ( Pt 6): 2001-7.  
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/420398doi: bioRxiv preprint first posted online Sep. 17, 2018; 
Joel et al 2018 bioRxiv preprint v2 
Page 34 of 47 
33. Duff K, Knight H, Refolo LM, et al. Characterization of pathology in transgenic mice 
over-expressing human genomic and cDNA tau transgenes. Neurobiol Dis 2000;7: 
87-98. DOI:10.1006/nbdi.1999.0279. 
34. Cummings DM, Liu W, Portelius E, et al. First effects of rising amyloid-beta in 
transgenic mouse brain: synaptic transmission and gene expression. Brain : a 
journal of neurology 2015;138: 1992-2004. DOI:10.1093/brain/awv127. 
35. Ridha BH, Barnes J, Bartlett JW, et al. Tracking atrophy progression in familial 
Alzheimer's disease: a serial MRI study. Lancet Neurol 2006;5: 828-34. 
DOI:10.1016/S1474-4422(06)70550-6. 
36. Pardon MC, Sarmad S, Rattray I, et al. Repeated novel cage exposure-induced 
improvement of early Alzheimer's-like cognitive and amyloid changes in TASTPM 
mice is unrelated to changes in brain endocannabinoids levels. Neurobiol Aging 
2009;30: 1099-113. DOI:10.1016/j.neurobiolaging.2007.10.002. 
37. Rattray I, Pitiot A, Lowe J, et al. Novel cage stress alters remote contextual fear 
extinction and regional T2 magnetic resonance relaxation times in TASTPM mice 
overexpressing amyloid. J Alzheimers Dis 2010;20: 1049-68. DOI:10.3233/JAD-
2010-091354. 
38. Rattray I, Scullion GA, Soulby A, Kendall DA, Pardon MC. The occurrence of a deficit 
in contextual fear extinction in adult amyloid-over-expressing TASTPM mice is 
independent of the strength of conditioning but can be prevented by mild novel cage 
stress. Behav Brain Res 2009;200: 83-90. DOI:10.1016/j.bbr.2008.12.037. 
39. Howlett DR, Richardson JC, Austin A, et al. Cognitive correlates of Abeta deposition 
in male and female mice bearing amyloid precursor protein and presenilin-1 mutant 
transgenes. Brain Res 2004;1017: 130-6. DOI:10.1016/j.brainres.2004.05.029. 
40. Foley AM, Ammar ZM, Lee RH, Mitchell CS. Systematic review of the relationship 
between amyloid-beta levels and measures of transgenic mouse cognitive deficit in 
Alzheimer's disease. J Alzheimers Dis 2015;44: 787-95. DOI:10.3233/JAD-142208. 
41. Kobayashi DT, Chen KS. Behavioral phenotypes of amyloid-based genetically 
modified mouse models of Alzheimer's disease. Genes Brain Behav 2005;4: 173-96. 
DOI:10.1111/j.1601-183X.2005.00124.x. 
42. Spires-Jones TL, Meyer-Luehmann M, Osetek JD, et al. Impaired spine stability 
underlies plaque-related spine loss in an Alzheimer's disease mouse model. 
AmJPathol 2007;171: 1304-11.  
43. Kirkwood CM, Ciuchta J, Ikonomovic MD, et al. Dendritic spine density, morphology, 
and fibrillar actin content surrounding amyloid-beta plaques in a mouse model of 




All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/420398doi: bioRxiv preprint first posted online Sep. 17, 2018; 
Joel et al 2018 bioRxiv preprint v2 
Page 35 of 47 
Figure 1 Tau protein expression and phosphorylation in TauD35 mice 
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Western blots were performed using antibodies specific to various Tau epitopes and 
quantified by normalising intensities to HSPA9. A) The human Tau-specific antibody 
HT7 demonstrates the TauD35 transgene is translated into protein. Two-way ANOVA 
genotype x age interaction, p<0.002.  B) The pan-Tau antibody DA9 was used to examine 
total Tau (endogenous mouse and transgenic human).  Values are normalised to wild 
type Tau levels.  Note the different sized bands evident in wild type. Two-way ANOVA, 
main effects of genotype (p<0.003) and age (p<0.01); age x genotype interaction p=0.06; 
Sidak post hoc tests at 4 months: p<0.01, 13 months p>0.2). C) Levels of pS202-Tau 
(CP13. Age x genotype interaction: p<0.0001.  D) Levels of pS396/S4040-Tau (PHF-1).  
Two-way ANOVA age x genotype interaction: p<0.05.  E) Human Tau (HT7) within the 
sarkosyl-insoluble fraction.  Note, Amido black (total protein) was used as a loading 
control, however, the low levels of protein in this fraction makes quantification 
impractical.  Sample sizes (animals) for all probes are indicated by the numbers within 
columns in panel D. Sidak post hoc tests with respect to wild type are indicated by 
*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; and with respect to LowTAU by † p<0.05; 
†† p<0.01; ††† p<0.001; †††† p<0.0001. 
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Figure 2 Neuronal cell loss in TauD35 mice. 
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A)  Cresyl violet stained sections of brain from 18-month-old animals showing 
hippocampus, dorsal ventricle and surrounding cortex.  Note the distinct shrinkage of 
total brain tissue, an enlargement of the ventricle and thinning of the cortex in the 
HighTAU mice.  Scale bar: 500 μm.  B) Sections of primary neuronal cell body layers of 
CA1, CA3 and dentate gyrus stained in brown for AT8 (Tau) and counter stained with 
cresyl violet.  Insets show mislocation of Tau to the somatic and dendritic compartments 
and neurofibrillary tangle-like structures within the soma in Tau mice. Scale bar: 50 μm. 
C) Neuronal cell counts in CA1 and CA3 indicate substantial cell loss.  CA1: Two-way 
ANOVA age x genotype interaction for wild type v HighTAU mice, p<0.03. Sidak post hoc 
test **p<0.01. No significant main effects or interaction for wild type v LowTAU. 
(Separate two-way ANOVAs run for LowTAU v wild type and HighTAU v wild type to 
accommodate missing age groups). CA3: main effect of genotype, p<0.01.  NB. HighTAU 
mice do not survive beyond 16.5-19 months of age; n=2-4 per genotype per age. 
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Figure 3 Neurofibrillary tangles in HighTAU mice 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/420398doi: bioRxiv preprint first posted online Sep. 17, 2018; 
Joel et al 2018 bioRxiv preprint v2 
Page 40 of 47 
Ai) Overall image of transverse section of hippocampus from a 13-month-old HighTAU 
mouse, double stained using HT7 (human Tau, red) and nuclei (DAPI, blue). (Composite 
image using a 20x objective on an EVOS FL Auto Cell Imaging System.) Scale bar: 200 
μm. Aii) CA3 region of a 4-month-old HighTAU mouse double stained using CP13 (S202) 
and DAPI. Note diffuse Tau staining within all cellular compartments, in particular the 
somatodendritic compartment. Scale bar: 20 μm. Aiii) A single CA3 neurone from Ai 
showing twisted Tau filaments filling the soma. Scale: 5 μm. (Images Aii and Aiii 
obtained using a Zeiss LSM 510 confocal microscope with 60x oil immersion objective.)  
Bi) Quantification of Tau immunofluorescence detected with either AT8/HT7 double 
staining, CP13, MC1 or PHF-1 in CA1. Bii) Data from Bi normalised to the number of 
neurones counted (Fig 2C).  C) Example immunofluorescence images obtained from CA1 
with each of the above antibodies.  Scale bar: 25 μm. 
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Figure 4 Microglia in TauD35 mice 
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A) Hippocampal sections showing microglia (Iba1, green) and pS202 Tau (CP13, red) 
from 13-month-old mice.  Hippocampal layers are indicated in the wild type 
micrographs (SO: stratum oriens; SP: stratum pyramidale; SR: stratum radiatum; SL: 
stratum lacunosum; SM: stratum moleculare; SG: stratum granulosum; SLM: stratum 
lacunosum moleculare.  Arrows indicate examples of microglia associating with Tau.  B)  
Colocalisation of CD68 (red) and Iba1 (green) in sections from 18-month-old animals.  C-
F) Quantification of CA1 layer-specific alterations in 4- 13-, 18- and 24-month-old mice 
for Iba1 positive microglia (left), CD68 positive microglia (i.e. where CD68 colocalised 
with Iba1; centre) and ratio of CD68 positive/total microglia (right).  NB, in some 
regions, there were no CD68 positive microglia identified. At 18 months only WT vs 
HighTAU and 24 months only WT vs LowTAU. Sidak post hoc tests following significant 
layer x genotype interactions are indicated compared to wild type *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001.  At 18 months of age (panel E), there was a main effect of 
genotype for the proportion of CD68 positive microglia, **p<0.05.  (NB, Sidak post hoc 
test for C&D were designed to also assess lowTAU versus highTAU, data not shown for 
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Figure 5 Synaptic transmission in TauD35 mice 
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A) Spontaneous excitatory transmission recorded from CA1 pyramidal neurones.  Ai) 
Example spontaneous and miniature EPSCs obtained from 13-month-old animals. Scale: 
10 pA x 20 ms Aii) Frequency; Aiii) Amplitude; Aiv) decay time constant (τ) for 
spontaneous and miniature EPSCs.  Sample sizes are indicated above the bars in Aii. 
Individual data for LowTAU and HighTAU mice are indicated to the right of each bar 
plot.  B) Evoked excitatory transmission.  Bi) Examples of EPSCs recorded from CA1 
pyramidal neurones and evoked by paired-pulses applied to Shaffer collaterals.  Scale 10 
pA x 20 ms.  Bii & iii) Paired-pulse ratio profiles obtained from CA3-CA1 synapses of 4- 
and 13-month-old animals.  Sample sizes are indicated in parentheses in Bii&iii.  Tukey 
post hoc tests are indicated in panel A (*p<0.05 versus wild type; †p=0.05) following 
one-way ANOVA and Sidak post hoc tests are indicated in panel B following significant 
genotype x interval interaction by two-way ANOVA (*p<0.05; **p<0.01). 
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Figure 6 Synaptic plasticity in Tau mice 
A) Input-output relationships at 4, 13 and 24 months of age.  fEPSPs from HighTAU mice 
(grey line, n=8) at 4 months of age, were smaller than wild type or LowTAU mice (n=9). 
B) Paired-pulse ratios from wild type and TauD35 mice across all ages. C) LTP induced 
by tetanic stimulation in 4-month-old animals.  Example traces from the time points 
indicated (1, 2) are shown above. D)  Magnitude of LTP from wild type and TauD35 mice 
across ages.  E)  Change in paired-pulse ratio following induction of LTP. (Two-way 
ANOVA main effect of genotype but not age).  Sample sizes (animals) are indicated above 
the bars in panel D. 
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Figure 7 Cognitive assessment of TauD35 mice 
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A) Performance of mice during the training phase of the T-Maze. Wild type: n=10; 
LowTAU n=9; HighTAU n=2. Aii) The effect of introducing delays between sample and 
choice runs.  Two-way ANOVA, no effect of genotype, or interaction between genotype x 
delay.  Aiii&iv) Response times in the sample (iii) and choice (iv) runs across training 
blocks. B) Open field arena.  Bi) Total pathlengths over the first 15 minutes of the open 
field exploration. Bii) Pathlengths within 5 minute periods of the open filed exploration.  
Biii)  Habituation within the open field indicated by an activity change score [block 
15/sum(block 5+block15)].  One-sample t-tests from 0.5 (i.e. no-change in activity) are 
denoted by ***p<0.001.  Biv) Relative dwell time in the peripheral area of the open field. 
C) Light/Dark box.  Ci) Latency to 1st entry into the dark box (one-way ANOVA: p=0.06); 
Cii) latency to re-enter dark box; Ciii) Proportion of time spent in the dark box (NB, 
given the size proportions of the two boxes, 0.4 would be chance level.)  There was a 
significant correlation between Tau transgene copy number and time spent in the dark 
compartment (* p=0.05). 
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